# Cetuximab+mFOLFOX6 VS. mFOLFOX6 Alone in RAS/BRAF Wild Type Patients With High-Risk Resectable CRLM

> **NCT05948072** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Fudan University** · enrollment: 250 (estimated)

## Conditions studied

- Colorectal Cancer
- Liver Metastases

## Interventions

- **DRUG:** mFOLFOX6 + Cetuximab
- **DRUG:** mFOLFOX 6

## Key facts

- **NCT ID:** NCT05948072
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2023-07-15
- **Primary completion:** 2026-07-15
- **Final completion:** 2026-07-15
- **Target enrollment:** 250 (ESTIMATED)
- **Last updated:** 2023-07-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05948072

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05948072, "Cetuximab+mFOLFOX6 VS. mFOLFOX6 Alone in RAS/BRAF Wild Type Patients With High-Risk Resectable CRLM". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05948072. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*